Critical Survey: Senesco Technologies (SVON) versus Its Rivals
Senesco Technologies (OTCMKTS: SVON) is one of 95 public companies in the “Biotechnology” industry, but how does it compare to its peers? We will compare Senesco Technologies to related businesses based on the strength of its analyst recommendations, profitability, earnings, risk, dividends, valuation and institutional ownership.
Earnings and Valuation
This table compares Senesco Technologies and its peers top-line revenue, earnings per share and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Senesco Technologies||N/A||-$2.26 million||-1.29|
|Senesco Technologies Competitors||$224.58 million||$58.11 million||-1.06|
Senesco Technologies’ peers have higher revenue and earnings than Senesco Technologies. Senesco Technologies is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
This table compares Senesco Technologies and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Senesco Technologies Competitors||-912.91%||-186.15%||-28.31%|
This is a breakdown of recent recommendations and price targets for Senesco Technologies and its peers, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Senesco Technologies Competitors||122||460||1151||11||2.60|
As a group, “Biotechnology” companies have a potential upside of 52.37%. Given Senesco Technologies’ peers higher probable upside, analysts clearly believe Senesco Technologies has less favorable growth aspects than its peers.
Institutional & Insider Ownership
20.4% of shares of all “Biotechnology” companies are owned by institutional investors. 25.1% of Senesco Technologies shares are owned by insiders. Comparatively, 19.6% of shares of all “Biotechnology” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Volatility and Risk
Senesco Technologies has a beta of 1.19, meaning that its share price is 19% more volatile than the S&P 500. Comparatively, Senesco Technologies’ peers have a beta of 1.13, meaning that their average share price is 13% more volatile than the S&P 500.
Senesco Technologies peers beat Senesco Technologies on 5 of the 9 factors compared.
Senesco Technologies Company Profile
Sevion Therapeutics, Inc. is a development-stage biotech company. The Company is engaged in building and developing a portfolio of therapeutics, from both internal discovery and acquisition, for the treatment of cancer and immunological diseases. The Company is engaged in the development and licensing of technology to discover and engineer monoclonal antibodies. The Company’s product candidates are derived from multiple technology platforms, such as cell-based arrayed antibody discovery, ultralong antibody scaffolds and Chimerasome nanocages. The Company has various antibodies in its preclinical pipeline. The Company’s antibody therapeutic candidates target the potassium channel, voltage dependent (Kv1.3) ion channel, which is essential in the pathogenesis of several autoimmune and inflammatory disorders. Other antibodies in its pipeline target cell surface molecules involved in cancer progression.
Receive News & Ratings for Senesco Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Senesco Technologies Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.